Abiopharma

Director Farrell Michael J. 🟡 adjusted position in 5.0K shares (1 derivative) of RESMED INC (RMD) at $248.46 ($2.7M) Transaction Date: Jan 07, 2026 | Filing ID: 000003

Organon sluit een akkoord voor de commercialisering van Daiichi Sankyo’s Nilemdo® in Frankrijk, Denemarken, IJsland, Zweden, Finland en Noorwegen

Organon sottoscrive un accordo di commercializzazione relativo a Nilemdo® di Daiichi Sankyo in Francia, Danimarca, Islanda, Svezia, Finlandia e Norvegia

Grifols Sa (GIFLF) Files Form 6-K

Organon schließt Vermarktungsvereinbarung für Nilemdo® von Daiichi Sankyo in Frankreich, Dänemark, Island, Schweden, Finnland und Norwegen

Organon firma un acuerdo de comercialización para Nilemdo® de Daiichi Sankyo en Francia, Dinamarca, Islandia, Suecia, Finlandia y Noruega

New Form SCHEDULE 13G/A - Anika Therapeutics, Inc. Filed: 2026-01-08 AccNo: 0001104659-26-002059 Size: 21 KB

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial

New Form 144/A - Monte Rosa Therapeutics, Inc. Filed: 2026-01-08 AccNo: 0001965301-26-000002 Size: 5 KB

New Form 5 - Bespoke Extracts, Inc. Filed: 2026-01-08 AccNo: 0001213900-26-002478 Size: 6 KB

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Lillys Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

agilon health, inc. (AGL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation